Skip to main content
BOTANIX PHARMACEUTICALS LTD logo

BOTANIX PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · BOT ISIN · AU000000BOT2 ASX Manufacturing
Open in API
Filings indexed 1,209 across all filing types
Latest filing 2022-09-25 Regulatory Filings
Country AU Australia
Listing ASX BOT

About BOTANIX PHARMACEUTICALS LTD

https://botanixpharma.com/

Botanix Pharmaceuticals Ltd is a clinical-stage pharmaceutical company focused on the development and commercialization of novel topical treatments for serious skin conditions. The company utilizes its proprietary Permetrex™ skin delivery technology, which is designed to improve the delivery of active ingredients through the skin. Its primary product, Sofdra™ (sofpironium bromide), is an FDA-approved prescription topical gel for the treatment of primary axillary hyperhidrosis. The company's research and development pipeline also includes clinical-stage candidates for the treatment of acne, rosacea, and atopic dermatitis. Botanix aims to address significant unmet medical needs in dermatology by providing innovative therapeutic solutions with enhanced safety and efficacy profiles.

Recent filings

Filing Released Lang Actions
BOT Submits FDA New Drug Application for Sofpironium Bromide 3 pages 249.6KB
Regulatory Filings Classification · 95% confidence The document is a press release dated 26 September 2022 announcing the submission of a New Drug Application (NDA) to the FDA by Botanix Pharmaceuticals for Sofpironium Bromide. It highlights the clinical trial results, the target FDA approval timeline, and the company's transition to a commercial dermatology company. There are no financial statements, detailed financial performance data, or regulatory certifications. The document is an announcement of a significant corporate event related to regulatory submission and product development, not a financial report or detailed investor presentation. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Investor Presentation. It is a regulatory announcement about a drug approval submission, which aligns best with the Regulatory Filings (RNS) category as a general regulatory announcement that does not fit other specific categories.
2022-09-25 English
Annual Report to shareholders 76 pages 985.5KB
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT for the year ended 30 June 2022' and contains detailed sections typical of an annual report, including Directors' Report, Auditor's Independence Declaration, Consolidated Financial Statements, Notes to the Financial Statements, Directors' Declaration, Independent Auditor's Report, Corporate Governance Statement, and Additional ASX Information. The content includes comprehensive financial data, management discussion, and corporate information. The document length is 15,000 characters, indicating it is a full report rather than a brief announcement. There is no indication that this is merely an announcement of a report or a certification. Therefore, this document fits the definition of an Annual Report (10-K equivalent).
2022-09-15 English
Appendix 4G 13 pages 295.4KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3. It is a form used by ASX-listed entities to confirm compliance with corporate governance disclosure requirements. The document includes a key to where governance disclosures can be found, and it is lodged simultaneously with the annual report. It is not the annual report itself, nor a full corporate governance statement, but a verification and key document related to governance disclosures. The document is lengthy (15,000 characters) and contains detailed governance compliance information, but it is not a full report like an Annual Report (10-K) or Governance Information (CGR) report. Given the nature of the document as a regulatory compliance filing related to governance disclosures, it best fits the Regulatory Filings (RNS) category, which is the fallback for miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2022-09-15 English
Ceasing to be a substantial holder 1 page 250.5KB
Regulatory Filings
2022-09-12 English
Change in substantial holding 3 pages 99.9KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of change in interests of substantial holder under Corporations Law 671B. It details changes in voting power and relevant interests of a substantial shareholder in the company, including dates and particulars of shareholding changes. This type of filing is a notification of changes in significant share ownership levels, which matches the definition of Major Shareholding Notification (MRQ). The document is not a financial report, management information, or any other type of report but a regulatory notice about shareholding changes.
2022-09-12 English
Annual General meeting 2 pages 117.3KB
AGM Information Classification · 95% confidence The document is a notice announcing the scheduling of the 2022 Annual General Meeting (AGM) for Botanix Pharmaceuticals Limited, including details about the date, business items such as director re-election, and nomination deadlines. It does not contain the actual AGM materials or presentations, nor does it include financial statements or detailed reports. The document is relatively short (3759 characters) and serves as an announcement rather than the AGM report itself. Therefore, it fits the category of AGM Information (AGM-R).
2022-09-11 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.